Figure 5. IL-17F and IL-22 do not enhance ASM contraction, and IL-17A requires IL-17RC.

(a) Contractile force measurements from tracheal rings treated for 12 hours with or without 100 ng ml⁻¹ IL-17F or IL-22 and stimulated with MCh or KCl. (b) Dose-response curves of tracheal rings treated for 12 hours with or without increasing doses of IL-17A, IL-17F or IL-22 and stimulated with 1 mM MCh or 60 mM KCl. *P < 0.05 in IL-17A treated samples compared to control, IL-17F, or IL-22 treated samples. (c) Tracheal smooth muscle samples were treated with 100 ng ml⁻¹ IL-17A, IL-17F, or IL-22 for 12 hours and 1 mM MCh for 15 minutes. Samples were then lysed, separated by SDS-PAGE, transferred to a membrane, and probed with antibodies to Ser-19 phosphorylated MLC, total MLC, and GAPDH. (d) Contractile force measurements from tracheal rings isolated from control or Il17rc^−/− mice treated for 12 hours with or without 100 ng ml⁻¹ IL-17A and stimulated with increasing doses of MCh or KCl. *P < 0.05 and **P < 0.01 in IL-17A treated control samples compared to Il17rc^−/− mice. (e) Pulmonary resistance measurements after administration of acetylcholine in control and Il17rc^−/− mice immunized and intranasally challenged with OVA or saline. *P < 0.05 in OVA treated control mice compared to OVA treated Il17rc^−/− mice.